Advertisement
Advertisement
U.S. markets close in 4 hours 19 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Innovent Biologics Inc (6IB.MU)

Munich - Munich Delayed Price. Currency in EUR
4.7800+0.0200 (+0.42%)
As of 08:03AM CEST. Market open.
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
Previous Close4.7600
Open4.7800
Bid4.6800 x N/A
Ask4.8600 x N/A
Day's Range4.7800 - 4.7800
52 Week Range2.9000 - 5.3500
Volume1,200
Avg. Volume18
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for 6IB.MU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • The Wall Street Journal

      Health Care Roundup: Market Talk

      0734 GMT – Innovent Biologics ’ earnings may be hit by some developments including delays in general procurement from Chinese hospitals starting 3Q, owing to a change in sentiment toward ambitious marketing by drugmakers, CCB International Securities analysts say in a research report. After factoring in the biotech company’s recent capital-raising and boosting the brokerage’s research & development cost estimates for 2023-2025, CCB International Securities lifts its 2023 and 2024 net-loss forecasts for Innovent Biologics by 7% and 70%, respectively. Its forecast of a net profit in 2025 also changes to a projection of a net loss, adds the brokerage, which cuts the stock’s target price to HK$44.50 from HK$47.00 with an unchanged outperform rating.

    • PR Newswire

      Innovent Announces 2023 Interim Results and Business Updates

      Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, announces its 2023 interim results and major company business updates.

    • PR Newswire

      Innovent Announces the NMPA Approval of SINTBILO® (Tafolecimab Injection) for the Treatment of Adult Patients with Primary Hypercholesterolemia and Mixed Dyslipidemia

      Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, announces that China's National Medical Products Administration (NMPA) has approved SINTBILO® (tafolecimab injection, anti-PCSK9 monoclonal antibody) for the treatment of adult patients with primary hypercholesterolemia (including heterozygous

    Advertisement
    Advertisement